SCHEMBL6350091

SCHEMBL6350091

CC(=O)Nc1ccc(S(=O)(=O)c2ccc(NC(=O)[C@@](C)(O)C(F)(F)F)c(Cl)c2)cc1

nearest known ligand 0.76

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ABCB11 O95342 1/20 0.76
PDK1 Q15118 11/20 0.70
PDK2 Q15119 11/20 0.70
PDK3 Q15120 11/20 0.70
PDK4 Q16654 11/20 0.70
ABCC9 O60706 7/20 0.64
ABCC8 Q09428 7/20 0.64
KCNJ11 Q14654 7/20 0.64
KCNJ8 Q15842 7/20 0.64
MEN1 O00255 1/20 0.60
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2D6 P10635 1/20 0.60
TSHR P16473 1/20 0.60
CYP2C19 P33261 1/20 0.60
KMT2A Q03164 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6350096 1.00 ABCB11 (0.76) ABCB11PDK1PDK2PDK3PDK4
SCHEMBL6571168 0.91 ABCB11 (0.76) ABCB11PDK1PDK2PDK3PDK4
SCHEMBL6571176 0.91 ABCB11 (0.76) ABCB11PDK1PDK2PDK3PDK4
SCHEMBL6571094 0.90 ABCB11 (0.74) ABCB11PDK1PDK2PDK3PDK4
SCHEMBL6571088 0.90 ABCB11 (0.74) ABCB11PDK1PDK2PDK3PDK4
SCHEMBL5737112 0.89 PDK1 (0.67) ABCB11PDK1PDK2PDK3PDK4
SCHEMBL6569536 0.89 ABCB11 (0.73) ABCB11PDK1PDK2PDK3PDK4
SCHEMBL6449596 0.89 ABCB11 (0.59) ABCB11PDK1PDK2PDK3PDK4
SCHEMBL6569135 0.88 ABCB11 (0.71) ABCB11PDK1PDK2PDK3PDK4
SCHEMBL6569720 0.88 ABCB11 (0.78) ABCB11PDK1PDK2PDK3PDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960688-B2 Use of compounds for the elevation of pyruvate dehydrogenase activity ASTRAZENECA AB (SE) 2005-11-01 US disclosed
US-20040009979-A1 Use of compounds for the elevation of pyruvate dehydrogenase activity ZENECA LIMITED 2004-01-15 US disclosed
US-6498275-B1 Use of compounds for the elevation of pyruvate dehydrogenase activity ASTRAZENECA AB (SE) 2002-12-24 US disclosed
EP-1082110-A1 USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY AstraZeneca AB (SE) 2001-03-14 EP disclosed
WO-1999062506-A1 USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY ASTRAZENECA AB (SE) 1999-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009979-A1 Use of compounds for the elevation of pyruvate dehydrogenase activity PDHA1, PDK1, PDHB ABCB11 325/4885PDK1 2/4885PDK2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.